GO
Loading...

GlaxoSmithKline PLC

More

  • NEW YORK, Oct. 1- Two tiny companies are preparing to challenge some of the world's largest drug makers in the battle for dominance in the $3 billion global market for influenza vaccines, armed with little more than tiny tobacco plants.

  • *Roche set to compete with established GSK combination. *Shares in Roche's biotech partner Exelixis jump 20 pct. MADRID, Sept 29- Rival two-pill combinations for melanoma from Roche and GlaxoSmithKline had similarly good results in separate clinical trials, leaving doctors with little to choose between the two skin cancer courses.

  • Royal Bank of Scotland chairman to step down Thursday, 25 Sep 2014 | 4:38 AM ET

    LONDON— Philip Hampton, the chairman of the Royal Bank of Scotland Group, has announced that he's leaving the company and joining the board of GlaxoSmithKline to become chairman in 2015.. Britain bailed out RBS, which remains 81 percent taxpayer-owned.

  • LONDON, Sept 25- GlaxoSmithKline said on Thursday it had chosen Philip Hampton, who currently chairs Royal Bank of Scotland, as its next chairman. GSK was hit last week by a record $489 million fine in China for bribing doctors and has warned on profits in 2014 due to weak sales of its core respiratory drugs.

  • GSK chooses Philip Hampton as next chairman Thursday, 25 Sep 2014 | 3:10 AM ET

    LONDON, Sept 25- GlaxoSmithKline said on Thursday it had chosen Philip Hampton, who currently chairs Royal Bank of Scotland, as its next chairman.

  • Inovio to start human trials of Ebola vaccine Wednesday, 24 Sep 2014 | 11:28 AM ET

    Sept 24- Vaccine developer Inovio Pharmaceuticals Inc said the company and its partner GeneOne Life Science Inc will start testing its experimental Ebola vaccine in humans in the first half of 2015.. Two other vaccine candidates in development are from GlaxoSmithKline Plc and NewLink Genetics Corp..

  • WASHINGTON/ SHANGHAI, Sept 23- U.S. regulators will pay a record $30 million bounty to an anonymous whistleblower outside the United States, underlining the growing reach of the country's watchdogs and creating a headache for global firms in fast-growing emerging markets.

  • LONDON, Sept 22- GlaxoSmithKline may have closed one chapter in a saga of corruption allegations by accepting a $489 million fine in China, but the drugmaker has its work cut out to win back sceptical investors.

  • Business Highlights Friday, 19 Sep 2014 | 5:47 PM ET

    NEW YORK— Alibaba debuted as a publicly traded company Friday and swiftly climbed more than 40 percent in a mammoth IPO that offered eager investors seemingly unlimited potential for growth and a way to tap into the burgeoning Chinese middle class.

  • China fines GlaxoSmithKline $492M for bribery Friday, 19 Sep 2014 | 4:22 AM ET

    BEIJING— Drug maker GlaxoSmithKline was fined $492 million on Friday for bribing doctors in China, the biggest such penalty ever imposed by a Chinese court. The court sentenced the company's former China manager, Briton Mark Reilly, and four Chinese co-defendants to prison but postponed the sentences for two to four years, suggesting they may never be served.

  • BEIJING— China fines British drug maker GlaxoSmithKline $492 million, jails executives in bribery case.

  • The candidate Ebola vaccine is being co-developed by the United States National Institutes of Health and the British drugmaker GlaxoSmithKline. The trial will be led by Professor Adrian Hill of the Jenner Institute at Oxford University, which said on Friday the first shot is scheduled to be given to a human volunteer next week.

  • LONDON/ NEW YORK, Sept 12- As electronic cigarettes flew off shelves on both sides of the Atlantic in recent years, investors flocked to a business some hope will be the future for tobacco.

  • The worst-ever Ebola outbreak, which has already killed at least 2,296 people in West Africa, has triggered a scramble to develop the first drug or vaccine for a deadly disease that was discovered nearly 40 years ago in the forests of central Africa.

  • JOHANNESBURG, Sept 10- Aspen Pharmacare is to sell the rights to market a blood clot drug in the United States to rival Mylan Inc for up to $300 million, it said on Wednesday, a move that would help Africa's top generic drugmaker pay down debt.

  • SHANGHAI/ WASHINGTON, Sept 9- A U.S. anti-bribery probe into GlaxoSmithKline Plc touched on the firm's Chinese consumer healthcare business in 2012, internal documents show, suggesting the drugmaker's compliance problems in China could go wider than previously revealed.

  • Sept 4- NewLink Genetics Corp said the U.S. Food and Drug Administration allowed the company to start testing an experimental Ebola vaccine in humans. The move follows a decision to begin initial human testing of a GlaxoSmithKline vaccine this month and an approval to fast track tests of a Johnson& Johnson vaccine.

  • Sept 3- Chimerix Inc said its lead experimental drug showed promise against the deadly Ebola virus in laboratory testing at the U.S. Centers for Disease Control and Prevention and the National Institutes of Health.

  • Sept 2- The U.S. Department of Health and Human Services said on Tuesday a federal contract worth up to $42.3 million would help accelerate testing of an experimental Ebola virus treatment that is being developed by privately held Mapp Biopharmaceutical Inc..

  • PRESS DIGEST-Sunday British Business - AUG 31 Sunday, 31 Aug 2014 | 9:28 AM ET

    LONDON, Aug 31- British newspapers reported the following business stories on Sunday. GlaxoSmithKline is facing a shareholder revolt over plans to shake up its board, with leading investors calling for the speedy departure of Chairman Christopher Gent.